Lionheart Health, Inc. announced the filing of a non-provisional U.S. patent covering its platform technology: Bioelectric-Enhanced Klotho Nanoflowers for Aging Reversal and Healthspan Extension. The patent protects a therapeutic system that integrates nanoflower-format nanoparticles, bioelectric signaling sequences, and Klotho-modulating biologics to target cellular and mitochondrial drivers of aging.
The platform centers on engineered "nanoflowers"—flower-shaped hybrid nanoparticles capable of upregulating Klotho, a longevity-associated protein linked to improved brain, kidney, cardiovascular, and metabolic health. These nanoparticles also restore mitochondrial function by enhancing ATP production and reducing oxidative stress, deliver targeted bioactive agents including peptides and genetic tools, act as nanozyme catalysts to reduce reactive oxygen species, and enhance regenerative signaling when activated by precise bioelectric patterns. The nanoflowers are engineered to respond to Lionheart's proprietary bioelectric stimulation sequences, which increase cellular uptake and activate intracellular pathways.
Howard J. Leonhardt, Founder and CEO of Lionheart Health, stated that the invention represents the convergence of bioelectric signaling, nanomedicine, and Klotho modulation. The goal is to create a system that reverses biological age at the cellular level and enhances healthspan safely and non-invasively. The nanoflowers require bioelectric activation for optimal performance, with signals designed to open ion channels, improve endocytosis, direct nanoflowers toward mitochondria, and trigger therapeutic payload release.
Klotho expression increases due to both nanoflower-delivered payloads and bioelectric activation of promoter and epigenetic pathways, demonstrating a combined therapeutic benefit mechanism. The system is designed for system-wide healthspan improvement, including mitochondrial biogenesis, reduction of cellular senescence, and stabilization of biological age. Klotho is recognized as a promising longevity molecule, with decreased levels associated with accelerated aging, cognitive decline, inflammation, and organ dysfunction.
Dr. Leslie Miller, Chief Medical Officer, noted that bioelectric-enhanced Klotho nanoflowers provide a programmable, multi-modal tool to address root causes of aging like declining energy production and rising inflammation. The patent filing adds to Lionheart Health's intellectual property portfolio, which spans bioelectric-controlled protein expression, stem-cell mobilization, mitochondrial restoration, and Klotho-based therapies. Optional components include closed-loop adaptive control using sensors to adapt stimulation patterns and multi-modal integration with other regenerative supports.
Lionheart Health is preparing for expanded clinical evaluation within its network of Lionheart Longevity & Wellness Licensed Clinics and plans to integrate the technology into its XPRIZE Healthspan competition program. More information is available at https://www.LionheartHealthStim.com and https://www.LionheartLongevity.com.
